Allergan Comments On Key Presentations At The Association for Research in Vision and Ophthalmology Meeting.

IRVINE, Calif.--(BUSINESS WIRE)--May 13, 1999--

During the recently staged Association for Research in Vision and Ophthalmology (ARVO) meeting in Ft. Lauderdale, Florida, Allergan scientists and collaborators presented data on a broad range of ophthalmic research and development activities. Allergan products and research and development programs were the subject of over 30 podium and poster presentations.

Presentation subjects included, but were not limited to, laboratory data demonstrating the neuroprotective effects of brimonidine (the active ingredient in Alphagan(R)); several new clinical studies on Alphagan(R) (brimonidine); new evidence in animal models of the neuroprotective effects of Memantine; Phase II clinical data on the Hypotensive Lipid AGN 192024 compound; and Phase III data on Restasis(TM) (topical cyclosporine) for the treatment of moderate to severe dry eye. Commenting on the ARVO meeting, Dr. Lester Kaplan, Allergan's President R&D said, "the breadth and quality of the work presented by Allergan at ARVO is evidence of the innovation taking place at our research laboratories."

Updating key late stage development activities, Allergan reports that the U.S. Food and Drug Administration has accepted for filing the Restasis(TM) New Drug Application and has assigned the file a priority review.

Forward-looking Statement 

Any of the above statements that refer to Allergan's estimated or anticipated future results are forward-looking and reflect the Company's current analysis of existing trends and information. Actual results may differ from current expectations based on a number of factors affecting Allergan's businesses, including the timing and uncertainty of the results of both research and regulatory processes, and including the research, development, regulatory approval, introduction and consumer acceptance of new products. Additionally, there can be no assurance that the U.S. Food and Drug Administration will ultimately approve Restasis(TM), or approve Restasis(TM) for the indication currently sought, or approve it on an expedited basis. These forward-looking statements represent the Company's judgment only as of the date of this press release. Actual results could differ materially from those projected in this release. As a result, the reader is cautioned not to rely on these forward-looking statements. The Company disclaims, however, any intent or obligation to update these forward-looking statements.

Allergan, Inc. headquartered in Irvine, California, is a technology-driven, global health care company, providing eye care and specialty pharmaceutical products worldwide. Allergan develops and commercializes products in the eye care pharmaceutical, ophthalmic surgical device, over-the-counter contact lens care, movement disorder, and dermatological markets that deliver value to our customers, satisfy unmet medical needs and improve patients' lives.